CVS Health and Fresenius Medical Care: A Tale of Two Healthcare Giants
Table of Contents
Despite operating within the broader healthcare services sector, CVS Health and Fresenius Medical Care pursue distinct strategies and cater to different patient needs. CVS Health has established itself as a leading health solutions company, offering a comprehensive suite of insurance products and expanding into technology-driven care. Conversely, Fresenius Medical Care specializes in providing essential products and services for individuals battling kidney disease, notably dialysis treatments for approximately 300,000 patients globally.
CVS Health: Expanding Reach and Diversified Growth
CVS Health has been actively bolstering its retail presence through strategic acquisitions. The company recently finalized the purchase of select assets from Rite Aid, adding 63 former Rite Aid and Bartell Drugs stores across Idaho, Oregon, and Washington, along with prescription files from 626 pharmacies spanning 15 states. This expansion increases CVS Health’s patient base by over nine million individuals. Further demonstrating its commitment to accessible care, CVS Specialty Pharmacy will partner with the TrumpRx Fertility program, slated to launch in January 2026, aiming to lower the cost of fertility treatments.
The company’s diversified business model is proving resilient. According to a company release, the Pharmacy & Consumer Wellness segment remains a key driver of performance, fueled by over 9,000 retail locations and ongoing investments in both technology and its workforce. CVS CostVantage, a cost-based pricing framework, is gaining traction, establishing transparent reimbursement based on actual drug costs, markups, and dispensing fees. CVS plans to extend this model to several government service programs in 2026.
Within its Health Services division, CVS Health is experiencing significant growth. Patient acquisition at Oak Street and increased volume at Signify Health contributed to a 19% revenue increase in the healthcare delivery business during the second quarter of 2025. Caremark, CVS Health’s pharmacy benefit manager, continues to prioritize affordability and access, particularly in the competitive GLP-1 drug category. Aetna, a CVS Health company, also received positive recognition, with over 81% of its Medicare Advantage members enrolled in 4-star plans and more than 63% in 4.5-star plans, as highlighted in the Centers for Medicare & Medicaid Services 2026 Star Ratings.
As of June 30, CVS Health reported $11.79 billion in cash and cash equivalents, and maintained its regular quarterly dividend of $0.665 per share. Despite these strong financials, the company acknowledges ongoing cost pressures and potential macroeconomic challenges. At its Capital Markets Day in June, CVS Health unveiled its new FME Reignite strategy, focused on leading kidney care through innovation and enhanced patient care.
Fresenius Medical Care: Reigniting Growth in Kidney Care
Fresenius Medical Care is actively pursuing a new strategic direction with its FME Reignite initiative. The company invested EUR 312 million and completed a share purchase agreement with non-physician investors in Interwell Health (IWH), its value-based care asset, and appointed a new leader for the operating segment. Value-Based Care saw benefits from expanded contracting in the second quarter of 2025, resulting in increased Member Months.
Fresenius Medical Care is also advancing its technological capabilities, with broader U.S. commercialization of the 5008X CARE system, a key step in introducing high-volume hemodiafiltration (HVHDF) therapy to individuals with kidney disease. Demonstrating a commitment to global health equity, the company partnered with the Coordination of National Institutes of Health and Specialty Hospitals to launch a pilot program providing low-income patients in Mexico without medical coverage access to HVHDF therapies.
The company’s FME25+ program aims to generate sustainable savings through operational efficiencies across its manufacturing and supply chain. The expanded program now targets cumulative savings of €1.05 billion by the end of 2027, including an additional €300 million from operational improvements. This strategy supports Fresenius Medical Care’s goal of achieving a mid-teens percentage operating income margin by 2030.
Under the FME Reignite strategy, Fresenius Medical Care is prioritizing shareholder value. The company plans to invest between EUR 800 million and EUR 1 billion annually in capital expenditures from 2025 to 2030 to support sustainable growth. The company is also lowering its net financial leverage target to between 2.5X and 3.0X and implementing a dividend policy with a 30-40% payout ratio. However, the company remains vulnerable to fluctuations in global trade policy and broader macroeconomic factors, which could impact costs and profitability.
Investment Outlook: CVS Health Leads the Way
Year-to-date, CVS shares have surged 82.5%, significantly outpacing Fresenius Medical Care’s 20.3% growth. Based on the forward price-to-sales (P/S) ratio, CVS shares are trading at 0.25, below their five-year median of 0.28, while FMS trades at a five-year P/S ratio of 0.67, above its median. CVS carries a Value Score of A, compared to FMS’s Value Score of B.
The Zacks Consensus Estimate for CVS Health’s 2025 EPS projects year-over-year growth of 17.3% to $6.36, with estimates trending upward over the past 90 days. Meanwhile, the consensus EPS estimate for Fresenius Medical Care signals 30.7% year-over-year growth, but estimates have shown a mixed trend recently.
CVS Health’s robust retail expansion, the strength of its diversified divisions, and its solid financial foundation position it favorably for long-term success. Fresenius Medical Care has initiated its new strategy, with ambitious profitability goals and a revised capital allocation framework. While both companies anticipate year-over-year earnings growth in 2025, CVS Health’s superior share performance, consistent earnings revisions, and more attractive valuation make it the stronger investment choice at this time. Both CVS and FMS currently carry a Zacks Rank #3 (Hold).
